

Mike Ufer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5572118/publications.pdf>

Version: 2024-02-01

28
papers

1,157
citations

430874
18
h-index

501196
28
g-index

28
all docs

28
docs citations

28
times ranked

1330
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative Pharmacokinetics of Vitamin K Antagonists. <i>Clinical Pharmacokinetics</i> , 2005, 44, 1227-1246.	3.5	248
2	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. <i>Thrombosis and Haemostasis</i> , 2010, 103, 572-585.	3.4	119
3	Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 19-26.	5.7	80
4	Identification of cytochromes P 450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 173-182.	1.9	69
5	Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 147-152.	1.9	65
6	Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 493-499.	1.9	54
7	Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2588-2597.	2.8	53
8	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y ₁₂ receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 3132-3140.	2.2	52
9	Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. <i>Pharmacogenomics</i> , 2009, 10, 1941-1953.	1.3	44
10	Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y ₁₂ Receptor Antagonists. <i>Clinical Pharmacokinetics</i> , 2020, 59, 545-566.	3.5	44
11	Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 779-783.	1.9	40
12	Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography–mass spectrometry after solid-phase extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 809, 217-226.	2.3	34
13	Influence of CYP3A4, CYP3A5, and ABCB1 Genotype and Expression on Budesonide Pharmacokinetics: A Possible Role of Intestinal CYP3A4 Expression. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 43-46.	4.7	29
14	Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. <i>Xenobiotica</i> , 2004, 34, 847-859.	1.1	28
15	Clinical Pharmacology of the Reversible and Potent P2Y ₁₂ Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male Subjects. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 123-130.	2.0	27
16	Metabolism and Disposition of the Metabotropic Glutamate Receptor 5 Antagonist (mGluR5) Mavoglurant (AFQ056) in Healthy Subjects. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1626-1641.	3.3	23
17	Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. <i>Sleep</i> , 2022, 45, .	1.1	23
18	Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. <i>Sleep</i> , 2021, 44, .	1.1	22

#	ARTICLE	IF	CITATIONS
19	Antimicrobial drug use in hospitalised paediatric patients: a cross-national comparison between Germany and Croatia. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 735-739.	1.9	19
20	Achiralâ€“chiral LC/LCâ€“MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism. <i>Analytical Biochemistry</i> , 2005, 339, 297-309.	2.4	17
21	Effect of the novel dual orexin receptor antagonist daridorexant on nightâ€“time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease. <i>Journal of Sleep Research</i> , 2021, 30, e13248.	3.2	15
22	Determination of(R)- and(S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2004, 18, 458-464.	1.5	13
23	Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes. <i>Analytical and Bioanalytical Chemistry</i> , 2005, 383, 909-917.	3.7	12
24	The selective metabotropic glutamate receptor 5 antagonist mavoglurant (<sc>AFQ</sc>056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13058.	3.0	10
25	Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. <i>Thrombosis and Haemostasis</i> , 2021, 121, 755-766.	3.4	9
26	Effects of polymorphisms on phenprocoumon anticoagulation status. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 335-336.	4.7	5
27	Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2022, 61, 687-695.	3.5	2
28	Off-label paediatric prescribing in Stockholm (Sweden): a response to a letter to the editor. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 493-494.	1.9	1